Data validates multimodal AI biomarker’s ability to help inform treatment decisions omCSPC

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

New data validated a multimodal artificial intelligence-based biomarker’s ability to help inform treatment decisions for patients with oligometastatic castration-sensitive prostate cancer, including metastasis-directed therapy benefit. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

For localized prostate cancer, multimodal artificial intelligence models have revealed a more accurate way to assess prostate cancer risk.  By combining advanced artificial intelligence with digital pathology images and clinical data, researchers developed a way to approach risk classification that outperforms traditional methods. These findings were published in JCO Precision Oncology. The research found that...

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login